Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the JAK2/STAT3 signaling pathway

Eur J Pharmacol. 2023 Mar 5:942:175529. doi: 10.1016/j.ejphar.2023.175529. Epub 2023 Jan 20.

Abstract

Osteosarcoma is the most common primary bone malignancy in children and adolescents; it exhibits rapid growth and a high metastatic potential and may thus lead to relatively high mortality. The JAK2/STAT3 signaling pathway, which plays a critical role in the occurrence and development of osteosarcoma, is a potential target for the treatment of osteosarcoma. Here, we identified the natural product telocinobufagin (TCB), which is a component isolated from toad cake, as a potent candidate with anti-osteosarcoma effects. TCB inhibited osteosarcoma cell growth, migration, invasion and induced cancer cell apoptosis. Mechanistically, TCB specifically inhibited the JAK2/STAT3 signaling pathway. More importantly, TCB significantly suppressed tumor growth and metastasis in an osteosarcoma xenograft animal model. Moreover, TCB also showed strong inhibitory effects in other cancer types, such as lung cancer, liver cancer, colon cancer, breast cancer and gastric cancer. Hence, our study reveals TCB as a potent anti-osteosarcoma therapeutic agent that inhibits the JAK2/STAT3 signaling pathway.

Keywords: Growth and metastasis; JAK2; Osteosarcoma; STAT3; Telocinobufagin.

MeSH terms

  • Animals
  • Apoptosis
  • Bone Neoplasms* / metabolism
  • Cell Line, Tumor
  • Cell Movement
  • Cell Proliferation
  • Humans
  • Janus Kinase 2 / metabolism
  • Osteosarcoma* / pathology
  • STAT3 Transcription Factor / metabolism
  • Signal Transduction
  • Xenograft Model Antitumor Assays

Substances

  • telocinobufagin
  • Janus Kinase 2
  • STAT3 Transcription Factor
  • JAK2 protein, human
  • STAT3 protein, human